Windward Bio’s WIN378 Delivers Positive Phase 2 Asthma Data as Twice-Yearly Anti-TSLP Antibody Moves Into Phase 3
Windward Bio has reported positive interim Phase 2 results for WIN378, also known as HBM9378 or SKB378, showing sustained improvements in lung function and key inflammatory biomarkers after a single dose in patients with uncontrolled asthma. With a…
China’s Personalized mRNA Cancer Vaccine Race Accelerates After Moderna and Merck’s Phase 3 Melanoma Success
The personalized cancer vaccine field has reached a major inflection point. Moderna and Merck announced on August 19, 2026 that their Phase 3 INTerpath-001 trial of intismeran autogene (V940/mRNA-4157) plus KEYTRUDA (pembrolizumab) met both its primary…
Haisco Pharmaceutical Group
From Chinese Specialty Pharma to Global Innovative Drug Developer
Akeso, Inc.
Building a Global Bispecific Antibody and Next-Generation Oncology Franchise
Akeso’s Ivonescimab Beats Durvalumab Standard in Phase 3 Biliary Tract Cancer Trial
Akeso’s PD-1/VEGF bispecific antibody ivonescimab has delivered another major Phase 3 victory, this time outside lung cancer, demonstrating a statistically significant overall survival advantage over durvalumab plus chemotherapy in first-line advanced…
DAJO Bio Raises Tens of Millions of RMB in Seed Financing to Advance Next-Generation TCR Protein Therapies
Shenzhen-based biotechnology startup DAJO Bio (“DAJO”) has completed a seed financing round worth tens of millions of RMB, providing fresh capital to advance its next-generation T-cell receptor (TCR) protein therapeutic platforms and pipeline…
MagicRNA raises hundreds of millions of yuan in Series B financing to advance world’s first in vivo CAR-T therapy
Recently, Shenzhen MagicRNA Biotechnology Co., Ltd. (or MagicRNA) announced the completion of a Series B financing round of several hundred million yuan. This round was led by a fund under CICC Capital, co-led by Kangjun Capital , with participation from…
Haisco’s class 1 small-molecule PNH drug has been approved for marketing in China
Today (July 23), the National Medical Products Administration (NMPA) of China announced that it has approved the marketing of Haisco Pharmaceutical‘s Class 1 innovative drug, Succinate Spocoman tablets (HSK39297), through the priority review and…